We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,816

China's crackdown on counterfeit medicines won "IPR Defenders Award" in the United States
  • Unitalen
  • China, USA
  • April 28 2014

The "Cloud Action" by Chinese police to combat cyber crime of producing and selling fake drugs, won the "IPR Defenders Award" awarded by the Global

The disclosure of "transfers of value" in the life sciences sector
  • Taylor Wessing
  • China, European Union, United Kingdom
  • September 30 2013

Investigations have recently been reported into allegations that millions of pounds worth of bribes have been paid to boost drug sales in China. This

China newsletter, Summer 2014 No. 27
  • Greenberg Traurig LLP
  • China
  • July 31 2014

On February 20, 2014, the State Administration for Industry and Commerce published the Administrative Provisions on the Registration of the

China’s anti-graft campaign: implications for multi-nationals operating in China
  • Dechert LLP
  • China
  • May 30 2014

Chinese anti-corruption efforts historically targeted recipients of bribes, particularly government officials. In the past year, however, Chinese

China’s Patent Re-Examination Board says pharmaceutical salts not patentable over pure compounds
  • Greenberg Traurig LLP
  • China
  • August 14 2013

In July 2013, the Patent Re-Examination Board of China's State Intellectual Property Office invalidated the U.S. biotech company, Gilead Sciences'

China: life sciences regulatory crackdown spreads to medical device sector
  • Reed Smith LLP
  • China
  • August 15 2013

On August 15, 2013, the local Beijing office of the Ministry of Health (MOH) of the People's Republic of China announced (Chinese link) that it has

CFDA restructuring plan aims for more effective regulatory approvals
  • Freshfields Bruckhaus Deringer LLP
  • China
  • August 7 2013

As a part of the ministerial restructuring of the State Council, the re-named China Food and Drug Administration (the CFDA) now a ministerial-level

The NDRC has begun a wide-ranging investigation into drug pricing
  • Freshfields Bruckhaus Deringer LLP
  • China
  • August 7 2013

On 2 July 2013 the National Development and Reform Commission (the NDRC) opened a wide-ranging, two-part investigation into the prices and pricing

Pharmaceutical industry in China: hot issues and update from HFG staff
  • HFG Law & Intellectual Property
  • China
  • June 13 2013

Stringent regulation in the key emerging markets (China, India, ASEAN) impacts the strategy of international companies. While the biggest players

China solicits comments on post-market study guidelines
  • Ropes & Gray LLP
  • China
  • October 29 2013

The Center for Drug Evaluation ("CDE") in China recently published the draft Guidelines for the Administration of Post-Market Studies on Chemical